Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung Cancer - Episode 4

HER2-Directed Agents in NSCLC

,

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Overview of Antibody Drug Conjugates in Lung Cancer
EP. 2: ADCs in Development for the Treatment of Lung Cancer
EP. 3: Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
Now Viewing
EP. 4: HER2-Directed Agents in NSCLC
EP. 5: Targeting HER3 in EGFR-Mutant NSCLC
EP. 6: Exploring TROP2 Expression in Patients with NSCLC
x